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Abstract
Purpose A meta-analysis was performed to evaluate the prognostic value of neutrophil-lymphocyte ratio (NLR) in patients
undergoing potentially curative gastrectomy for cancer (GC).
Methods Thomson Reuters Web of Science, Ovid MEDLINE(R) and PUBMED databases were searched for relevant articles
using search terms neutrophil-lymphocyte ratio (NLR), GC and survival. Articles reporting overall survival (OS), cancer-specific
survival and disease-free survival (DFS), in patients undergoing R0 gastrectomy, were studied.
Results Articles numbering 365 were identified during the preliminary search, and 10 containing 4164 patients were included in
the final review. Most patients were > 60 years of age, male (67%) and 2239 (53.8%) had pT3 disease. The number of NLR
dichotomization thresholds reported numbered 7, with 2.00 and 3.00 (n = 2) the most common. NLR was associated with poor
survival in eight studies with hazard ratios ranging from 1.54 (95% confidence interval (CI) 1.26–1.89) to 2.99 (1.99–4.49).
Pooled odds ratio (OR) for OS was 2.31 (1.40–3.83, p = 0.001) and for DFS 2.72 (1.14–6.54, p = 0.020). Four studies presented
T-stage data, OR 1.62 (1.33–1.96, p < 0.001).
Conclusion NLR is an important prognostic indicator associated with both OS and DFS after R0 resection of GC, but the critical
level is equivocal.
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Introduction
Going by the numbers, gastric cancer (GC) is the fifth
most common worldwide cancer diagnosis, and third
commonest cause of cancer-related death, accounting for
some one million (951,000) new annual diagnoses and
723,000 deaths. [1] Despite earlier diagnosis and im-
proved treatment, nearly one-third of patients undergoing
potentially curative surgery experience disease recurrence
[2, 3] and new prognostic biomarkers would therefore be
very welcome.
The systemic inflammatory response (SIR) is a com-
plex bio-system comprising humoral and cellular compo-
nents that protect the host from harmful pathogens, and a
range of SIR biomarkers has been reported to be associ-
ated with poor outcomes in gastric cancer. [2, 4] One such
biomarker is the neutrophil to lymphocyte ratio (NLR),
based on measurement of the hosts’ circulating immune
cells. Reports have associated the NLR with poor out-
come; however, studies were not exclusive to patients
undergoing potentially curative resection and the value
of NLR in this patient cohort is unclear. Moreover,
NLR’s value in guiding the use of adjuvant treatment
following potentially curative surgery is uncertain. This
systematic review and meta-analysis were therefore per-
formed to estimate the prognostic value of NLR in pa-
tients undergoing potentially curative gastrectomy and to
identify any correlation with histo-pathological T-stage.
Katie L Mellor and Arfon G. M. T. Powell contributed equally to this
work.
* Arfon G. M. T. Powell
powella16@cardiff.ac.uk
1 Wales Post Graduate Medical and Dental Education Deanery School
of Surgery, Cardiff University, Cardiff CF14 4XW, UK
2 Division of Cancer and Genetics, Cardiff University, University
Hospital of Wales, Heath Park, Cardiff, UK
Journal of Gastrointestinal Cancer (2018) 49:237–244
https://doi.org/10.1007/s12029-018-0127-y
# The Author(s) 2018
Methods
Search Protocol
The outcome measures chosen were overall (OS) and disease-
free survival (DFS). Thomson Reuters Web of Science, Ovid
MEDLINE(R) and PUBMED databases were searched for
relevant articles published between 1990 and October 2017.
The following search terms were used: (neutrophil lympho-
cyte ratio OR neutrophil-lymphocyte ratio OR neutrophil-
lymphocyte OR neutrophil-lymphocyte-ratio OR NLR)
AND (gastr* OR gastric OR stomach) AND (carcinoma OR
adenocarcinoma OR malig* OR malignancy OR tumour OR
tumor OR neoplasms).
Study selection (inclusion and exclusion criteria)
All original scientific articles were considered for inclusion.
Reviews and book chapters were excluded, as were texts writ-
ten in languages other than English. Reports including surviv-
al analysis of patients who did not undergo surgery with
curative intent were excluded. Only studies related to the as-
sociation between NLR and survival in patients undergoing
potentially curative resection for gastric cancer were included
in the systematic review. Only studies reporting extractable
data related to OS or DFS were included in the meta-analysis.
Data Extraction
Two independent reviewers applied the inclusion criteria to
study abstracts and selected full papers for data analysis. Full-
text manuscript data was obtained by author (KM), and 50% of
articles underwent independent review (AP), with discrepancies
verified by consensus. For each study, baseline data (author,
year of publication, country, study period, total number of pa-
tients, gender, pTNM stage, neoadjuvant chemotherapy, adju-
vant chemotherapy and NLR categorisation thresholds) were
recorded. Outcomes were described as odds ratios (OR) with
95% confidence intervals. Where these were not reported, the
methods described by Parmar and Rogers were used to extract
data from Kaplan–Meier curves, or percentage survival. [5, 6]
Records idenﬁed
through Ovid
MEDLINE database
searching
(n = 143)
Records aer duplicates removed
(n = 365)
Records screened
(n = 365)
Records excluded:
Not relevant (n= 339)
Not full text (n = 7)
Not English (n = 3)
Full-text arcles assessed
for eligibility
(n = 16)
Full-text arcles excluded,
No speciﬁc NLR data for
curave resecons (n = 2)
No speciﬁc data for
survival (n = 1)
Not relevant (n = 1)
Included oesophageal ca
(n = 2)
Studies included in
qualitave synthesis
(n = 10)
Studies included in
quantave synthesis
(meta-analysis)
(n = 7)
Records idenﬁed
through PUBMED
database searching
(n = 164)
Records idenﬁed
through Web of
Science database
searching
(n = 315)
Fig. 1 Flowchart of literature
selection
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Quality Analysis
This meta-analysis was conducted in accordance with the
preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines. [7] The quality of the stud-
ies was measured using the Newcastle-Ottawa scale,
assessing the methodological quality of non-randomised
cohort studies for meta-analyses. Studies were judged by
two independent assessors, using a nine-point scale com-
prising analysis on the selection of the study group, the
comparability of cohorts and the ascertainment of out-
come. Scores above 6 points were taken to denote studies
of high methodological quality and were included in the
meta-analysis. Studies were excluded if methodological
quality was poor (Newcastle-Ottawa scores < 7). [8]
Statistical Analysis
Statistical analyses were performed using RevMan statistical
package (Review Manager (RevMan) Version 5.3.
Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014). Heterogeneity between studies was
measured by calculating the I2 statistic that was calculated
for an objective measure of heterogeneity. A fixed-effect me-
ta-analysis was performed in all cases, and where there was
appreciable heterogeneity (I2 > 50% or Chi-squared p value <
0.10), a random-effect model was used. Corresponding funnel
plots of Ln standard error as a function of effect size were used
to examine the effect of publication bias visually and were
statistically tested using Eggers test; p values > 0.05 were tak-
en as indicative of no publication bias. For meta-analysis,
absolute numbers of deaths, recurrences and pT-stages in the
high and low NLR cohorts were extracted.
Results
The initial electronic search yielded 365 studies, of which 349
were excluded based on abstract content (Fig. 1). Three hun-
dred and thirty-nine were not relevant, seven were not avail-
able as full texts, and three were not English language manu-
scripts. Of the 16 full text manuscripts evaluated, two did not
Table 1 Baseline data on included studies
Author Year Country Study
period
No. of
patients
Age
(years)
M/F
ratio
AJCC TNM
stage
Chemotherapy Study design Evidence
level
N-O
score
Dutta 2012 UK 1996–2009 120 Median
> 65
1.9:1 I = 56 (47%)
II = 27 (23%)
III = 37 (31%)
NA—38.3%
A—not stated
Retrospective IV 7
Fang 2017 China 2006–2010 190 Median
> 60
2.6:1 II = 65 (34%)
III = 63 (33%)
IV = 62 (33%)
NA—excluded
A—not stated
Retrospective IV 7
Jiang 2014 China 2005–2007 377 Median
64
2.0:1 I = 37 (10%)
II = 99 (26%)
III = 241 (64%)
NA—excluded
A—58.1%
Retrospective IV 8
Jung 2011 Korea 2004–2007 232a Median
63
Not stated III = 138 (59%)
IV = 94 (32%)
NA—excluded
A—not stated
Retrospective IV 7
Lieto 2017 Italy 2000–2015 297a Not stated 1.4:1 I = 107 (36%)
II = 122 (41%)
III =66 (22%)
IV = 2 (0%)
NA—9.1%
A—63.6%
Retrospective IV 8
Liu 2017 China 2000–2012 1056 Mean
58
2.1:1 I = 194 (18%)
II = 266 (25%)
III = 596 (56%)
NA—excluded
A—suitable stage II–III
Retrospective IV 7
Mohri 2016 Japan 2000–2011 404 Median
67
2.3:1 I = 260 (64%)
II = 70 (17%)
III = 74 (18%)
NA—not stated
A—not stated
Retrospective IV 7
Powell 2017 U.K. 2004–2016 291 Median 69 2.0:1 I = 79 (27%)
II = 92 (32%)
III = 120 (41%)
NA—15.5%
A—21.0%
Retrospective IV 7
Sun 2016 China 2000–2012 873 Median
59
2.1:1 I = 108 (12%)
II = 185 (21%)
III = 580 (66%)
NA—excluded
A—66.7%
Retrospective IV 7
Wang 2011 China 2006–2009 324 Not stated 2.3:1 III = 324 (100%) NA—excluded
A—64.8%
Retrospective IV 7
aOnly data for curative resections extracted
NA neoadjuvant, A adjuvant, N-O Newcastle-Ottawa
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include specific data for curative resections, one did not report
survival data, one was not relevant to the study topic and two
included data related to oesophageal cancer. Consequently, ten
studies were included for qualitative analysis (Table 1) [2,
9–17]. The median Newcastle-Ottawa quality score for these
studies was seven (range 7–8). All studies were retrospective
cohort studies of one or more regional institutions
representing level IV evidence.
The ten studies included a total of 4164 patients with a
mean sample size of 418 (range 120–1056). The majority
of patients were aged 60 years or older, with an age range
of 19 to 89 years and were predominantly male (mean M/
F ratio 2.1:1) (Table 1).
Seven studies included patients with pTNM stage I–III dis-
ease, and three also including patients with stage IV cancer, all
undergoing potentially curative resection (Table 1). The ma-
jority of study patients had pT3 disease (n = 2239, 53.8%),
with fewer patients reported to have locally confined disease
(pT1 = 841, 20.2% and pT2 = 926, 22.2%) and 3.8% reported
to have pT4 tumours (n = 158). Neoadjuvant chemotherapy
was given in three of the studies [2, 9, 13] and post-
operative chemotherapy was administered to patients in six
Table 2 Baseline data on included studies
Author Year Outcome
measure
NLR cut-off 5-year
survival
Justification of
cut-off value
Hazard ratio
(confidence
interval)
Association with survival
Dutta 2012 CSS < 2.5—low
2.5–5—
intermediate
> 5—high
N/A Not stated 1.19 (0.76–1.87) No association (p = 0.454)
Fang9 2017 OS < 2—low
≥ 2—high
89.5%
76.9%
Median values 2.32 (1.08–5.02) High NLR, poorer survival
(p = 0.032)
Jiang 2014 OS < 1.44—low
≥ 1.44—high
63.2%
36.6%
ROC curve analysis 1.60 (1.05–2.44) High NLR, poorer survival
(p = 0.030)
Jung 2011 DFS < 3—low
≥ 3—high
44.1%
13.0%
Quartiles 1.65 (1.09–2.52) High NLR, poorer survival
(p = 0.019)
Lieto 2017 DFS ≤ 3.22—low
> 3.22—high
72.6%
30.5%
Maximum log rank
statistics
2.99 (1.99–4.49) High NLR, poorer survival
(p < 0.001)
Liu 2017 OS < 2—low
≥ 2—high
62.0%
47.0%
Previous study 1.54 (1.26–1.89) High NLR, poorer survival
(p < 0.001)
Mohri 2016 OS ≤ 3—low
> 3—high
N/A ROC curve analysis 2.91 (1.71–4.94) High NLR, poorer survival
(p < 0.001)
Powell 2017 DFS and
OS
≤ 5.5—low
> 5.5—high
70.7%a
59.1%
Previous study a1.43 (0.78–2.65)
b1.01 (0.58–1.76)
NLR not associated with survival
(p = 0.249a and p = 0.975b)
Sun 2016 OS < 2.3—low
≥ 2.3—high
85.1%
57.0%
ROC curve analysis 1.66 (1.39–1.99) High NLR, poorer survival
(p = 0.001)
Wang 2011 OS ≤ 5—low
> 5—high
N/A Previous study 2.47 (1.21–5.05) High NLR, poorer survival
(p = 0.013)
CSS cancer-specific survival, DFS disease-free survival, OS overall survival, N/A not available
a Data for DFS
bData for OS
Fig. 2 Association between high NLR and overall survival (pooled analysis)
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of the studies. [2, 11, 13, 14, 16, 17] The proportions of pa-
tients receiving post-operative chemotherapy ranged from
21.0 to 66.7%.
The NLR critical values reported varied between studies
with the commonest value 2.00 and 3.00 (n = 2). Six studies
reported an association between high NLR and poor overall
survival, [10, 11, 14–17] two studies reported an association
between NLR and disease-free survival [12, 13] and one study
reported no association with cancer-specific survival [10]
(Table 2). Four studies reported an association between NLR
and advanced pT-stage. [10, 11, 14, 15]
Relationship Between NLR and Overall Survival
Five studies reported data related to overall survival in 2787
patients undergoing potentially curative R0 gastrectomy. The
pooled odds ratio was 2.31 (95% CI 1.40–3.83, p = 0.001).
Significant study heterogeneity was observed (χ2 = 24.49, df
4, p < 0.0001, I2 = 84%). The Forest plot for these results is
shown in Fig. 2.
Relationship Between NLR and Disease-Free Survival
Three studies reported data related to NLR and disease-
free survival, comprising a total of 820 patients undergo-
ing potentially curative gastrectomy. The pooled odds ra-
tio was 2.72 (95% CI 1.14–6.54, p = 0.020, Fig. 3). Once
again, significant study heterogeneity was observed (χ2 =
10.02, df 2, p = 0.007, I2 = 80%).
Relationship Between NLR and pT Stage
Four studies reported data related to pT stage comprising a
total of 2027 patients. The pooled odds ratio was 1.62 (95%
CI 1.33–1.96, p < 0.001, Fig. 4). No heterogeneity was ob-
served in this cohort (χ2 = 5.12, df 3 p = 0.160, I2 = 41%).
Discussion
This meta-analysis is the first to examine exclusively the prog-
nostic value of NLR in patients undergoing potentially cura-
tive R0 gastrectomy for cancer. The principal findings were
that no fewer than 40% of patients had an elevated pre-
operative NLR, in keeping with other gastric cancer meta-
analyses (range 36.5–59.8%). [3, 18–20] This patient cohort
was over 50% more likely to have higher pT stage, which was
associated with over two-fold risk of disease recurrence, and
commensurately poorer long-term cumulative survival. Yet,
the threshold for NLR dichotomization varied across eight
of the studies analysed, threatening any argument for incorpo-
rating NLR into a core prognostic algorithm. But such strong
predictive associations suggest that the systemic inflammatory
response has the potential to be an important therapeutic bio-
marker, meriting targeted research.
The NLR has been studied in a variety of solid cancers [21]
including breast [22], colorectal [23], esophageal [24], lung
[25] and pancreas [26]. Reported pooled hazard ratios for
NLR and OS have ranged from 1.40 in oesophageal cancer
[24] to 2.61 in pancreatic cancer [26], compared with 2.31 in
Fig. 4 Association between high NLR and T-stage (pooled analysis)
Fig. 3 Association between high NLR and disease-free survival (pooled analysis)
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this study. The reason for this is unclear, but may reflect the
different dichotomization thresholds reported related to the
spectrum of cancers studied. Here, 8 of 10 studies used differ-
ent dichotomization thresholds; similarly, 9 of 11 reported in
breast cancer, 4 of 16 in colorectal cancer, 6 of 7 in oesopha-
geal cancer, 10 of 15 in lung cancer and 4 of 11 in pancreatic
cancer. This heterogeneity in dichotomization thresholds is a
significant limiting factor in comparing findings between can-
cer types as well as individual articles grouped by anatomical
site, and efforts to standardise reporting of NLR methodology
are desirable to facilitate comparative research.
NLR is one among a spectrum of seven inflammation-
based prognostic biomarkers associated with poor survival
in gastric cancer [2], including CRP, albumin, Glasgow prog-
nostic score, platelet-lymphocyte ratio, neutrophil-platelet
score and lymphocyte-monocyte ratio. Inflammation has been
proven to play an important role in the development and/or
progression of several cancers due to carcinogenesis promo-
tion. [27, 28] Moreover, a meta-analysis of 2.3 million indi-
viduals reported a 25% reduction in the risk of gastric cancer
associated with NSAID use. [29] Any reasonable observer
would surely agree that attenuating the systemic inflammatory
response by means of non-steroidal anti-inflammatory drug
(NSAID) therapy holds promise. Unfortunately, given the po-
tential adverse side effects associated with routine NSAID
use, their indiscriminate peri-operative use would carry a pal-
pable and significant risk. Identifying responders who would
benefit the most is therefore an important dilemma to which
NLR may hold the key.
This meta-analysis has a number of inherent limitations.
Heterogeneity existed between studies, which may be ex-
plained by a number of factors, not least the variation in
NLR critical values and patient characteristics including
disease stage, age and treatment. All studies analysed were
retrospective in methodology, and cohort in nature, provid-
ing pooled rather than individual patient data. Not all re-
ported extractable data, limiting the number available for
analysis. NLR has been described as a possible prognostic
marker in other diseases such as the acute coronary syn-
drome, [30] and as such, the influence of NLR may not
necessarily be cancer specific, and attenuating the systemic
inflammatory response may promote survival irrespective
of the effect of malignancy, which is an arena that requires
clarification. In contrast, the study has several strengths.
Similar TNM stages and chemotherapy rates to other
meta-cohorts strengthen the reliability of the findings.
Previous meta-analyses included a heterogeneous mixture
of treatment intents, including both potentially curative as
well as palliative treatments, and this meta-analysis is the
first to exclusively examine NLR’s prognostic significance
after potentially curative R0 gastrectomy. The clinical
challenge is to identify which patients who have undergone
potentially curative resection might benefit from adjuvant
therapies because of their higher risk of disease recurrence,
regardless of pTNM stage.
In conclusion, despite improvements in staging and surgi-
cal technique, approximately one third of patients who under-
go potentially curative gastrectomy for cancer will suffer dis-
ease recurrence. [31]. NLR, derived and calculated from ab-
solute counts of serum lymphocytes and neutrophils, is rou-
tinely performed during pre-operative full blood count work-
up, and is therefore not only readily available but also inex-
pensive. Incorporating NLR into MDT algorithms to refine
and plan treatment strategies and predict prognosis is currently
limited by the variety and inconsistencies in reported dichot-
omization thresholds. Before this can be achieved, an ade-
quately powered study comparing critical dichotomisation or
categorisation threshold is needed to identify a pragmatic op-
timal critical ratio. Finally, further work should focus on es-
tablishing the prognostic value of NLR in patients suitable for
potentially curative gastric cancer surgery followed by
planned adjuvant anti-inflammatory treatment.
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